Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo

Maria Beconi, Omar Aziz, Kim Matthews, Lara Moumne, Catherine O'Connell, Dawn Yates, Steven Clifton, Hannah Pett, Julie Vann, Lynsey Crowley, Alan F. Haughan, Donna L. Smith, Ben Woodman, Gillian P. Bates, Fred Brookfield, Roland W. Buerli, George McAllister, Celia Dominguez, Ignacio Munoz-Sanjuan, Vahri Beaumont

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science